



# **Corrigendum: The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis** *via* **Modulating Multiple Signaling Pathways in Mice**

## Yongqiang Ai<sup>1†</sup>, Wei Shi<sup>1†</sup>, Xiaobin Zuo<sup>1†</sup>, Xiaoming Sun<sup>1†</sup>, Yuanyuan Chen<sup>1</sup>, Zhilei Wang<sup>1</sup>, Ruisheng Li<sup>2</sup>, Xueai Song<sup>3</sup>, Wenzhang Dai<sup>1</sup>, Wenqing Mu<sup>1</sup>, Kaixin Ding<sup>1</sup>, Zhiyong Li<sup>1</sup>, Qiang Li<sup>1</sup>, Xiaohe Xiao<sup>1,3</sup>\*, Xiaoyan Zhan<sup>1,3</sup>\* and Zhaofang Bai<sup>1,3</sup>\*

<sup>1</sup>Department of Hepatology, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China, <sup>2</sup>Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, <sup>3</sup>China Military Institute of Chinese Materia, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China

Keywords: schisandrol B, wedelolactone, hepatic fibrosis, combined pharmacotherapy, TGF- $\beta$ 1/Smads signaling pathway

## A Corrigendum on

## The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis via Modulating Multiple Signaling Pathways in Mice

by Ai, Y., Shi, W., Zuo, X., Sun, X., Chen, Y., Wang, Z., Li, R., Song, X., Dai, W., Mu, W., Ding, K., Li, Z., Li, Q., Xiao, X., Zhan, X., Bai, Z. (2021). Front. Pharmacol. 12:655531. doi: 10.3389/fphar.2021. 655531

In the original article, there was a mistake in **Figure 5** as published. The symbols (\*, \*\*, \*\*\*, ns) of statistic differences in **Figures 5B-F** were wrongly labeled. The wrongly labeled **Figure 5** was uploaded by accident when submitting the corrections of proof. The corrected **Figure 5** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2021 Ai, Shi, Zuo, Sun, Chen, Wang, Li, Song, Dai, Mu, Ding, Li, Li, Xiao, Zhan and Bai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

OPEN ACCESS

## Edited and reviewed by:

Salvatore Salomone, University of Catania, Italy

## \*Correspondence:

Zhaofang Bai baizf2008@hotmail.com Xiaoyan Zhan xyzhan123@163.com Xiaohe Xiao pharmacy\_302@126.com

<sup>+</sup>These authors have contributed equally to this work

## Specialty section:

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

> Received: 16 September 2021 Accepted: 21 September 2021 Published: 07 September 2021

#### Citation:

Ai Y, Shi W, Zuo X, Sun X, Chen Y, Wang Z, Li R, Song X, Dai W, Mu W, Ding K, Li Z, Li Q, Xiao X, Zhan X and Bai Z (2021) Corrigendum: The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis via Modulating Multiple Signaling Pathways in Mice. Front. Pharmacol. 12:777914. doi: 10.3389/fphar.2021.777914

1



**FIGURE 5** | A combination of SolB and WeD treatment dramatically inhibits hepatic fibrosis and injury in CCL4-induced hepatic fibrosis mice. (A) Images of livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB(40 mg/kg) and WeD(20 mg/kg). Representative micrographs of liver H&E staining, Sirius red, Masson and  $\alpha$ -SMA staining were shown. Scale bars represent 50 µm. (B–D) Quantitative results of Sirius red(B), Masson(C) and  $\alpha$ -SMA(D) staining sections. (E) Serum level of hydroxyproline of control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg) or combination of SolB and WeD. (F) Quantitative PCR analysis of mRNA levels of  $\alpha$ -SMA in livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg), weD(20 mg/kg), or combination of SolB and WeD. (G) Western blot analysis of Collagen1, p-Smad3, Smad2/3, p-IkBa, IkBa and GAPDH in livers from control, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg), WeD(20 mg/kg), or combination of SolB and WeD. Data are expressed as Mean  $\pm$  SD (n = 8 or 3 mice). Statistics differences were analyzed using One-way ANOVA followed by Tukey's